MUSC Hollings Cancer Center

Cancer Genes & Molecular Regulation

The scientific goal of the Hollings Cancer Center  Cancer Genes & Molecular Regulation (CGMR) Program is to identify novel genomic and genetic alterations that play causal roles in cancer development and to study genes, proteins, and signaling pathways that mediate the altered phenotypes of cancer cells. The three themes of research within this program are: 1) Cancer Genomics & Genetics: discovery, validation, and elucidation of the mechanisms of action of genomic alterations in cancer; 2) Molecular Regulation of Gene Expression:  abnormalities in the regulation of RNA stability and function, the action of miRNAs, and post-transcriptional regulation of gene expression in malignancy; and 3) Cell & Tumor Biology: cell signaling pathways and stroma and matrix factors that influence both cancer cell growth and stem cell biology.

CGMR Program Leader - Philip H. Howe, PhD

Cancer Genes & Molecular Regulation Program Members

Dr. Stephen P. Ethier talks about genomics research and how it's being applied in a clinical setting:


 ►  Listen to Dr. Ethier's recent podcast about cancer genomics on SC Public Radio (LISTEN)

Featured Research Project

howeRegulation of Transcript-Selective Translation by TGFβ: Deciphering the control of the TGFβ pathway is key to understanding the initiation, growth, and metastasis of multiple tumor types, including colon, prostate, and breast cancer.  Using breast cancer models, Dr. Philip H. Howe’s laboratory has delineated a novel post-transcriptional regulatory pathway by which TGFβ modulates expression of epithelial-mesenchymal transition (EMT)-inducer proteins and EMT itself.  Specifically, heterogeneous ribonucleoprotein E1 (hnRNP E1) and elongation factor 1A1 (EF1A1) form a mRNP complex that binds to a structural, TGFβ-activated translation (BAT) element in the 3’-UTR of EMT inducer transcripts and represses their translation. (MORE)




* This website is best viewed in Firefox or Chrome internet browsers.